SQ 29072
Latest Information Update: 23 Sep 1997
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Heart failure therapies
- Mechanism of Action Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 23 Sep 1997 No-Development-Reported for Hypertension in USA (Unknown route)
- 24 Oct 1994 Preclinical development for Hypertension in USA (Unknown route)